Figure 1
From: Molecular target based combinational therapeutic approaches in thyroid cancer
Estrogen treated thyroid cancer cells enhance angiogenesis of HUVECs. (A) Estrogen treated thyroid cancer cells enhance HUVEC migration. Conditioned medium from thyroid cancer cells with 10-8 M E2 ± 10-6 M fulvestrant was used as chemoattractant for HUVECs. The HUVECs that migrated and adhered on the lower surface of the membrane were fixed, stained, and counted in 10X field. The groups are as follows- HUVECs migrated to the untreated (black bars), E2 treated (grey bars) and E2 and fulvestrant treated (white bars) conditioned medium. Data expressed as numbers of HUVECs counted (migrated cells) per 10X field micrograph for each sample well and normalized to the untreated control set as 100%. The asterisk denotes statistically significant differences (p < 0.05) between experimental and untreated samples determined using a paired Student’s t - test. (B) Estrogen treated thyroid cancer cells enhance HUVEC proliferation. HUVECs were cultured in presence of thyroid cancer cell conditioned medium for 24 hours followed by trypan blue exclusion cell count to calculate endothelial cell proliferation. The groups are as follows- HUVECs cultured with untreated (black bars), E2 treated (grey bars) and E2 and fulvestrant treated (white bars) conditioned medium. Data expressed as % of HUVECs cell number normalized to the untreated controls set as 100%. The asterisk denotes statistically significant differences (p < 0.05) between experimental and untreated samples determined using a paired Student’s t – test. (C) Enhances tube formation of HUVECs induced by estrogen treated thyroid cancer cell conditioned medium. HUVECs were seeded in B-CPAP and ML-1 thyroid cancer cell conditioned medium on Growth factor-reduced Matrigel and were monitored for tubulogenesis. The results are representative of three independent experiments performed in triplicates.